atepeq/tico19 huggingface dataset:
mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
Tuany alirë piöu kor: kälau/pïu kuötnhïm në yɔ̈ɔ̈kyɔ̈ɔ̈kic, räpräpë piöör në baŋde yɔ̈ɔ̈kyɔ̈ɔ̈kic, räpräpde dïtë yɔ̈ɔ̈kyɔ̈ɔ̈k ce köc në nyiɛndeic, abiörde të laguɔkguɔk kekë käthii de riɛm ɣer ku jɔla räl thii kuötnhïm të röt loi.
severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates.
Tuany alirë piöu rillic: yɔ̈ɔ̈kyɔ̈ɔ̈k cë röt wɛɛr piny në rïäk(YWR) kekë yɔ̈ɔ̈kyɔ̈ɔ̈k cë röt wɛɛr piny në kuër.
DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
YWR e yenne cït ke dhurup në wëëï cɔkë ke juëc (CDWJ) ku jɔla dakë yic alir piɛth në riɛmic.
healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
Demde tuany alirë piöu: ajuɛɛr de kuër ë pïu tënë guäk ë yɔ̈ɔ̈kyɔ̈ɔ̈k ku jɔla nhiɛc dë räl ke yɔ̈ɔ̈kyɔ̈ɔ̈k.
Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
Riɛm: thiɛ̈i ë piny de riɛm të duöt në rälic (TRD); luɔide rim luɛt ku kä ɣer .
Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene and avoiding touching the eyes, nose or mouth with unwashed hands.
Käke gëlë aci purtha ë wuɔɔk dhuk piny anɔŋic dë bak, pɛ̈lde ɣän juëc kɔc thïn, lɔ̈k ë cin në athabun ku pïu alawɛ̈n ku të cït tënë monymony thii ka 20, piööc de wëëï piɛth ku pɛ̈l gɔ̈të nyin, um wälë thok në cin këcë cau/waak.
The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.
Aye CDC thany cök bï um ku thok aakum në dulgän të ɣɔlë wälë tïïmë ku aye lueel bï lɔŋde kɔr ya kuöm të cïn en dulgän tɔ̈.
Proper hand hygiene after any cough or sneeze is encouraged.
Juɛ̈rde cin apiɛth të raan ɣɔl wälë cë tïïm ayennë kɔc wɛi.
The CDC has recommended the use of cloth face coverings in public settings, in part to limit transmission by asymptomatic individuals.Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel and cancelling large public gatherings.
Aye CDC thany cök bï alath aa kuöm në kɔc nyïn të tɔ̈ kɔc në riɛmic/juɔ̈ric, ago wuɔɔk dhuɔ̈k nyin piny në kɔc cën gup cït ke tuany. Meecë yic wei e dɛ̈t thëm bë gɔ̈të kɔc cë wuɔɔk tɔ̈ në kɔc juɛ̈cic dhuɔ̈k nyin piny në thiöök de thukuul ku jɔla ɣän ke luɔi, miitë cäth nyin ku thiök mɛ̈të juör.
Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.
Dhöl kuany cök në baŋde meecë yic wei anɔŋic mɛn ye kɔc ke yic mɛɛc wei në të cït tënë mïtïr ka 6(1.8m).
There is no medication known to be effective at preventing COVID-19.As a vaccine is not expected until 2021 at the earliest, a key part of managing COVID-19 is trying to decrease the epidemic peak, known as "flattening the curve".
Acën wäl den yïlac nyic ëtɔ̈ bë KOBIT-19 gël. Kë ye wäl ë guöp gëlic e ŋɔ̈ɔ̈th kë bï jä yök në 2021 ic në dac bɛ̈nic. Kë ye mahëm në mɛ̈nyde KOBIT-19 e bï them bï nyin cï tuanyë döt dhuɔ̈k nyin piny, ë nyic kë ye cɔl "thööŋe nhomde kät".
The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing.
Aye CDC lueel ëyɛ mɛn bï kɔc ke cin aa lɔɔk alawɛ̈n në athabun ku pïu ne të cït tënë monymony thii ka 20, ten dhamɛn cï raan lɔ ror wälë të yennë aguɛl tïïŋ në kɔc cin, kë cäm ŋot ku jɔla të cï raan e um thöny, ɣɔl wälë tïïm.
It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production.
Ku aye lueel pe bï käkë wɛ̈kë cin e yiic naŋ-miöu lëu bï ya 60% në miöu, ku e të liu athabun ku pïu bïk ya tɔ̈. Tënë ɣän kök liu käke lɔɔkë cin ke thïn, APMP acë dhöl loi ëke gam bec bïnë ke ya loi.
In these formulations, the antimicrobial activity arises from ethanol or isopropanol.
Në ye dhölkä yic, luɔi de käm e rɔt jä jat nhial tenɔŋ miöu wälë isopropanol
Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis".
Hydrogen peroxide aye loi bïnë tut ke käm cop në miöuic; ace yen lui apiɛth në baŋde lɔ̈ɔ̈kë cin.
Glycerol is added as a humectant.
Glycerol aye mat thïn kë ye kë bë pïu amuk
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
Kɔc aye ke cɔ̈k piny në tïtë nyin, wɛ̈n lëu bë yic naŋ dɛ̈kë pïu ago guöp rot waar, konyde alïëër wëëï ku jɔla konyë käke guöp kök cë wuɔɔk e mahëm apɛi.
The CDC recommends that those who suspect they carry the virus wear a simple face mask.
Aye CDC thany cök bë kɔc e röt diw lɔn nɔŋ kek bairäth aa gël në kany në ke nyïn.
Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.
Tëu de alirde wëëï në räpräp ic bec (TAWR) acï ya loi kë yennë köcë wëëï dhuɔ̈k piny, lakin kä ken piɛth en aŋuɔtë ke tɔ̈ në ajuɛric.
Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.
Nuërë rɔtde ŋɛk ku jɔla pïr piɛthë pial ku cämë mïïth piɛth acï ya thany cök ë ye käk e guöp pial cök apiɛth.
Supportive treatments may be useful in those with mild symptoms at the early stage of infection.The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19.
Kuɛnyde yïlacɛt alëu bë luui tënë kɔc nɔŋ cït kor në piac gɔ̈l dë wuɔɔk ic. Käke thɛ̈nyë cök acï APMP ku Akutnhomë pande Caina mɛ̈t në käke Pial gät bec bï kɔc nyïn atït në kɔc cë wuɔɔk në KOBIT-19 cï tääc panakïm.
Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
Dïktoor ë nyïn tït në ayanïïn kucë ke pïrden ku jɔla dïktoor ë yɔ̈ɔ̈kyɔ̈ɔ̈k ku wëëï tɔ̈ U..S acë dhöl ke yïlacɛt cïke gam/thany cök mätïc tënë dutuuc kuöt ë ke käk e ke yök abac, kë ye IBCC.
As of April 2020, there is no specific treatment for COVID-19.
Mënë Akɔ̈nydït 2020, acën yïlany cï ya rok tënë KOBIT-19.
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.
Në baŋde cït, tuɛnydït cë piöc aaye paracëmol (acetaminophen) thany cök kë ye yen piɛth në ibupprofen kaŋ luɔi tueeŋ.
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.
Tïte nyin dhil bï jä lööm apiɛth agorë wuɔɔk kuɛr nyin piny, ku awïc bï ya bɛ̈i akïm yen en nyïn tït thïn apɛi në dhamɛn amälia en lëu bï thueithuei aliric lɔ bec, cït yïk tëude lïthïk në umic wälë kothë cïn në makanaic.
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
Tënë dïktoor cë piöc ë nyïn tït në ayanïïn ke KOBIT-19, aye CDC lueel bï raan ya täu në ɣön cï wɛ̈ŋ cï ɣokic në alir (ƔWƔA), ke ye mat ke dhöl piɛthde tïtë nyin/tiëtë röt, tiëtë röt në gɔ̈t ku tiëtë röt në alir. CDC acë dhöl buɔthic gam bec në baŋde käke ŋɛk yen röt gël (BKŊG) në dhamɛnde tuany cë dhoŋ bec.
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
Pärwil cï thany cök e: Geŋde BKŊG, kë dë wëëï wälë kanyë um, gëlde nyin, ku jɔla baloma akïm. Të tɔ̈ yen, käke wëëï (kë cï ber ya kanyde um) ka këk aaye ke lɔc.
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
Käke wëëï ë N95 aakä cï ke gam bec në löŋ bï ke ya loi ɣän ke cirgɛt lakin FDA acë kaany cɔkë ke ye loi në baŋde Gɛmë löŋ bï ke löï në wɛ̈të kë cë rot Tɛɛm(GLLWT).
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
Aacï ke loi bïk thueithuei thii tɔ̈ aliric cït yïk tɔr/Tut lakin acën piathden cï nyic në të cït të yen käke guöp luɔi thïn
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
Të liu kaany, ka ye CDC lueel bï akɔ̈n e kuöm në umic ya loi wälë bë ya yennë kën akär, kaany yeke loi bäï.
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
Kä juëc ke KOBIT-19 aacë rilic apɛi arɛ̈k bïk wïc në kooth alir wälë dɛ̈t wɛɛrë ye, lakin adɛn e käk në buɔɔtic aay.
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
Nuɔu ë konyde wëëï dë kɔc tuany në KOBIT-19 thïäk thok kekë köc dë wëëï agör cök apɛï tënɔŋ kɔc cï tääc panakïm, kekë kënë ye nyuɔth lɔn lëu bïne tëude lïthïk në umic puöl kekë ajoljolë pïu lɔ bec në lïthïŋ cï ciɛkë guöpic e pïu thɛ̈c bec wälë lerke thïn në guöpic wälë kanaden-bi piɛth ë dhölë cääth alir.
Whether either of these two leads to the same benefit for people who are critically ill is not known.
Akuc lɔn en kë nin në töŋ e käk yic karou lëu bë naŋ kë piɛth bɛ̈i tënɔŋ kɔc rïl tuanydɛnic apɛi.
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
Dïktoor kök aye kï nhiar bë makana alir mïɛt në umic ya rɛ̈ɛ̈r ke kɔc të tɔ̈ yen në wɛ̈t e yenë kän dhoŋ bec de thueithuei tɔ̈ aliric dhuɔ̈k nyin piny kë cë thöŋë kekë ajoljolë pïu lɔ bec në lïthïŋ cï ciɛkë guöpic. Kä rilic në baŋde tuany ajuëc apɛi tënë kɔc dït cë muk(kɔc dhiɔp wär ruɔ̈n 60 ku kök, ku kɔc cë dhiɔp wär ruɔ̈n 80 ku kök).
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
Bɛ̈i juëc cë lɔtueŋ në yïk de bäï aacën agɛn e ŋɛk nhom naŋ këde panakïm, kë ye luɔide ajuɛrë pial miɛ̈t nyin piny bï yen adɛn ë kä cë röt jatnhial në baŋde KOBIT-19 en rilic wïcë tɛ̈ɛ̈c.
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
Akuën töŋë nyïc ë loi Caina ecï yök ë 5% cï tääc ëke cïnë ke pïrdɛn täu në makanaic, 2.3% aake wïcë makana bë ke yiëk alir, ku jɔla 1.4% aacë thou.
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
Në pande Caina, aye thɔ̈ɔ̈ŋkɔ̈u kë kɔc ka 30% tɔ̈ panakïm ëke tuany në KOBIT-19 aake cï tääc ëke cïnë ke pïrdɛn täu në makanaic PTM.
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
Tëu de alir në kɔc um në makana acë bɛ̈n kë cï yic riɛ̈l apɛi në kë cï cït alir rac dït(CARD) në riɛmic röt loi në KOBIT-19 ic ku e lɔthïn alir piɛth në guöpic yic riɛl.
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
Käk alir gam lëu bïk kë rilic dhuɔ̈k piny ku jɔla LOOC tɔ̈ yic nhial aye wïc bë alir piɛth aa juakic ku e käk alir-juakic e yɔ̈ɔ̈kyɔ̈ɔ̈k diɛ̈t yiëk tëtöök ya dhuɔ̈k nyin piny ku tä alir babuur.
High PEEP may not be available on older ventilators.
LOOC tɔ̈ yic nhial acë lëu bë bɛ tɔ̈ tënɔŋ kä thɛɛr alir gam.
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
Yɔ̈ɔ̈p wïc bïnë yïlac yök e jɔk në Kön ic 2020, ku wɛl juëc ke tiëtë bairäth atɔ̈ në athëm ic.
Remdesivir appears to be the most promising.
Remdesivir e cït kë nɔŋ kë piɛth bë loi.
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
Acɔka lɔn ë bïnë wɛl jöt loi në 2021, wɛl juëc cï ke them aacï ke gam në loiloi kök wälë aatɔ̈ na thëm dït cï cuɔ̈tic cïën.
Antiviral medication may be tried in people with severe disease.
Wɛlë bairäth gël alëu bï them tënë kɔc nɔŋ tuany rilic.
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
Acï APMP thany cök bë kɔc cë röt gam abac bïk naŋ baŋ ye kï loi në thëm de luɔiden piɛth ku jɔla piathde yïlany lëu bë tɔ̈. FDA acë thëmë riɛ̈m de kɔc cë pial në tuanyic gam bec ëmääth kë nyothë yïlac të yïn en naŋ raan tɔ̈ pïrde të racic wälë tɔ̈ kë cë riɔ̈ɔ̈c.
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
Akën lɔ në akuën athëm akïm wïc bïnë ye nyuɔth en pialde ku piathde tënë tuany.
In February 2020, China launched a mobile app to deal with the disease outbreak.
Në Nyïth ic 2020, go Caina kë ye luui në tëlëpunic e cɔl app bɛ̈i bëï agorë lɔ bec ë tuany kuany cök.
Users are asked to enter their name and ID number.
Kɔc bë ëkënë tëlëpun ë ya loi aabï ke ya thiëëc bïk rinn ku nïmïra jïïnthiadɛn ya täu.
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
Yennë app kënë alëu bï 'thiökëic' moth në thönthii ke mukë nyin ku jɔla mëckëla ë wuɔɔk lëu bë rɔt.
Every user can also check the status of three other users.
En rɛn tɔ̈ kekë app ëbën alëu bë të yïn kɔc kadiäk kök tïŋ
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
Na nɔŋ mëckëla bë rɔt yök, kë app acce bë raan rɔt riɛm tëde ye tök yenne lueel, e bänyke pial lëk. Cääthëic dït thönthii në thönthii ë tɔ̈ ë tëlëpunic, tëknɔlojï yennë nyin nyic, kuënyë cök ë tëlëpun ku jɔla nyïnyë käŋ cï thɔ̈ŋkɔ̈u kekë nyïnyë raan aaye ke loi bïnë ke kɔc cë wuɔɔk kuany cök ku jɔla kɔc cë thïäk keke pande Thauth Koria, Taiwan ku Thiŋapor.
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
Në Köl ic 2020, go akuma dë Ithërɛl dutuuc e nyïn tït në macakël cɔkë ke kuany kɔc cë wuɔɔk në koronabairäth cök në thönthii ke tëlëpun
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
Kekë akarär kä aake loi ke ku bï rokë röt piny tɛ̈ntök aa loi ku gël kɔc lëu bïk thïäk kekë mïthë bäï cë wuɔɔk
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
Në Köl ic 2020 ëyɛ, go Deutsche Tëlëkom thönthii dë ɣän tɔ̈ tëlëpun thïn tuɔc tënë dutuuc akuma dë German, Thukulde Robert Koch, agorë yɔ̈ɔ̈p cök ku gël lɔ bec ë bairäth.
Russia deployed facial recognition technology to detect quarantine breakers.
Russia acë tëknɔlojï yennë nyïn ë kɔc nyic aci kɔc cë lööŋ dë tëuë rɔt tëntök në wɛ̈të tuany dhoŋkɔ̈th.
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
Mapɛ̈nh ë wäläya de käke pial pande Italy e cɔl Giulio Gallera aye lueel ka cï lɛ̈k në kɔc nɔŋ tëlëpun lɔn "40% de kɔc aaŋuɔtë ke lɔ ëke caath".
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
Akuma dë German eca matnhom de kɔc ë luui në käke cɔmpiöta loi në të cït thää 48 në thökë nïn ke läät kekë kë cït raan 42.000 cë röt juar.
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
Ëyɛ bënyde Estonia, ye cɔl Kersti Kaljulaid, acë pinynhom lɛ̈k ago kë piɛth thul lɔ bec ë koronabairäth loi.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
Kɔc alëu bïkë naŋ dhurup tënë rokë röt piny tën tök, cuɔ̈k thääth, mëckëla ye wɛl yiën kɔc në dhamɛnde yïlac wälë rïöc dë wuɔɔk.
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC acë Rory O'Connor piŋ kë jam, "juëkë wëŋë thök, nyinkök, ŋɛrëpiöu në baŋde pial, dhurup ku jɔla dhiɔmdë tujäria aakekë ya atiaktiak nëk kɔc nhïm ku nyiɛc rëër."
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
Tuany alëu bë lööm në kaam piɔlic kekë cït lik wälë cën cït, le thöŋ kekë tuɛnytuɛny juëc ke wëëï kök nɔŋ yïk thonythony.
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
Kä thii tuany piɔlic aaye dac pial në läätic kerou, ku kɔc nɔŋ tuany dït wälë tuany rilic apɛi alëu bïkë naŋ läät kädïäk agut cë läät kedhetem ku bïk jäl pial.
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
Diär liɛc alëu bïkë tä në mëckëladït lëu bï kek wuɔɔk në wuɔɔk rilic në KOBIT-19 në të cït të ye thönthii ke bairäth kök thöŋ yiën thïn, cït yïk SARS ku MERS lakin thönthii ke KOBIT-19 aaliu. Tënë kɔc kök, KOBIT-19 alëu bë yɔ̈ɔ̈kyɔ̈ɔ̈k ɣok ku le tuany alirë piöuic jɔk.
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
Tënë kɔc cïï mam yic riɛl thïn apɛi, KOBIT-19 alëu bë ɣet kë mɛ̈t e cök rɛ̈k bë cït ke dhurup kë wëëï cɔkë juëc (CDWJ) ke nɔk kɔ̈c de wëëï, riɛrë nhom wälë kɔ̈c de käkë në guöpic.
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
Kä ladɔkdɔk cï ke rek kekë KOBIT-19 aanɔŋiic abiörbör dë guöp, cuäc kamuöl de riɛm ku rïäk ë piöu, rok, ku jɔla cuëny.
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
Cuäcë riɛm kamuöl, në dhamɛn cï käkë cuäc kuɔny cök röt juak, acïï cäät tënë 6% ë kɔc cï tääc panakïm nɔŋ KOBIT-19, luɔi kamuöl de rok aye tïŋ tënë 4% de akutnhom.
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
Në thöŋë kɔ̈uic 20-30% de kɔc nɔŋ KOBIT-19 acë röt anyuɔth kë noŋë cuɛ̈ny cë röt jatnhial (transaminase)
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
Në të cït të ye kök e caal thïn, dhamɛn tɔ̈ cɛlic në kaam de ajöök ë cït ku thou eye nïn thiär, kekë dhïc ëke nɛ̈k në tɛ̈ɛ̈cic.
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
Kë yennë kɛy, ayanïïn cï lɔ awälu tënë ICU ake nɔŋ dhamɛn cɛlic de nïn kedhorou në kaamde tɛ̈ɛ̈c ku jɔla thou.
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
Tënë akuënë nyïnyde kä cë röt dac loi, kë dhamɛn cɛlic tënɔŋ nyöth de cït tueeŋ agut cë thää dë thou aaye nïn 14, kekë anuɛ̈t de nïn kedhetem agut cë nïn 41.
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
Në akuënë nyïcic ë loi Akutnhom ë Käke Pial Pande Caina (AKPPC), rör aake tɔ̈ thuɔnden në 2.8% ic ku jöl thonë diär bɛ tɔ̈ në 1.7% ic.
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
Cär akuënë nyïnyde räl cë rïäk de thïmthïm thii ke yɔ̈ɔ̈kyɔ̈ɔ̈k ë cë thou röt loi e nyuɔɔth ë tën alir në yɔ̈ɔ̈kyɔ̈ɔ̈k ic cë rɔt kärpiny në rïäk kekë räl thii ke fibromyxoid jɔl cuïï bei në yɔ̈ɔ̈kyɔ̈ɔ̈k ic käröu
Viral cytopathic changes were observed in the pneumocytes.
Gɛra de cytopathic bairäth e cï tïŋ në rälthii alir në yɔ̈ɔ̈kyɔ̈ɔ̈k ic.
The lung picture resembled acute respiratory distress syndrome (ARDS).
Thura dë yɔ̈ɔ̈kyɔ̈ɔ̈k athöŋ kekë cït ke dhurup ë wëëï cɔkë juëc (CDWJ).
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
Në 11.8% de thou cï caal në Akutnhom ë Käkë Pial Pande Caina, rïäk de piöu acï yök në jɛtë nhial dë troponin wälë kɔ̈c de piöu.
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
Në të cït tënë tbönthii kor kä tënɔŋ Amërika, 89% de kɔc cï tääc panakïm aake nɔŋ ɣälddɛn ë tɔ̈ wɛ̈nthɛɛr. Riɛl de käŋë/määlde wɛl ku jɔla täde kɔc kekë määl de wäläya alëu bï bë naŋ kë rɛc në pïric.
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
Thöŋë kɔ̈u de pïr tënë ɣäla äwääc në wɛ̈të wuɔ̈c e wäläya kä, lakin në wɛ̈të riɛlëic dhöl en ëke ye luɔi thïn ëyɛ.
The under-counting of mild cases can cause the mortality rate to be overestimated.
Cuök kuën apiɛth de kɔc nɔŋ tuany piɔlic alëu bë cinë pïr cɔkë le thöŋ kɔ̈u bë bɛrtueŋ.
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
Ëkɛy, në yiny e thuɔu yenna nëtïja de tuɛnytuɛny cë ya dɔmthɛɛr alëu bë thöŋë kɔ̈u de pïr nyuɔɔth kë tɔ̈ piny.
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
Kɔc ë mäth aake he arak 1.4 kök ëke lëu bïk naŋ cït kë KOBIT-19 rilic ku jɔla kä themke kɔ̈th në arak 2.4 aake ye yök ëke lëu bï ke täu në makanaic ago ke kuɔny në wëëï wälë thoukï në thon dït wär kɔc cë math. Adiɛr aacï dac jɔt nhïm në baŋde ɣälä dë tuany.
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
Kɔc ke löŋde panakïm Hong Kong e cïk yök kë yɔ̈ɔ̈kyɔ̈ɔ̈k cë dhuk piny në 20% agut cë 30% tënë kɔc kɔ̈k cë gup pial në tuany, ku Thura de yäkyäk aye nyuɔth kë këdɛ̈ cë rïääk.
This may also lead to post-intensive care syndrome following recovery.
Kënë alëu bë cït ke tïtë nyinde ayanïn nyuɔth batë pial ë guöp.
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
Mënë Kol 2020, e kuc lɔnë ye wuɔɔk thɛɛr en naŋ kë ye rac ku ye naŋ dhamɛn-bäric de käkë guöp gëlic tënë kɔc cë gup pial në tuany.
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
Kë ye guöp gëlic aye tïŋ kë lëu, në të ye koronabairäth kɔ̈k kä rëër thïn, lakin kä kɔ̈k cïnë ke pial tënë KOBIT-19 ya buɔth cök në thëmthëm piɛth dë koronabairäth në thää cë wɛn acï ya caal.
These cases are believed to be worsening of a lingering infection rather than re-infection.
Këkë aye ye ke gam në piöuic lɔn läkë riɛ̈k kek në wuɔɔk tai kë cë bërëic dë wuɔɔk.
The virus is thought to be natural and have an animal origin, through spillover infection.
Bairäth aye thɔ̈ŋic kë ye kenë tɔ̈ wɛ̈nthɛɛr ku e jɛ̈l cök tënë läi, në baŋde lathiëi piny de wuɔɔk.
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
Tënë dïk en ë jäl thïn akuc, lakin në Ɣɔ̈r de 2019 ic kë larär bec ë wuɔɔk ye kënë jɔl ŋɛk-ayïek-ŋɛk.
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
Akuën ë nyïc de käŋ ka 41 ɣɔn tueŋ kɔŋ ëke KOBIT-19 yök thïn, ë gätë bec në Kön ic 2020 lɔŋde Lancet, ecë dhamɛn ë dac cït jɔk nyuɔth kë Ɣɔ̈r e nïn 1, 2019.
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
Kë cï bäny ke APMP gät bec ecë luel yen dhamɛn ë jɔk cït röt kë Ɣɔ̈r e nïn 8, 2019.
Several measures are commonly used to quantify mortality.
Takatït juëc aloi ke ëmɛnku bï pïr themkɔ̈u.
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
Kekë adɛn käkë aawääc në wäläya yic ku tɛ̈ɛ̈k de dhamɛn ku aaye ke ger në cin de thëm, piathde luɔi ë panakïm, lööclööc de yïlac, thää ë jöök dhoŋë bec ë tuany ku jɔla të yïn juör thïn cït yïk run ke raan, e tik ka ye moc ku pial ebɛ̈n.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
Në thök de 2019, go APMP ecë nïmïra dë käkë röt tɛɛm de tuany ICD-10 cï thiankɔ̈u gam U07.1 de thou tënɔŋ wuɔɔk de SARS-CoV-2 cï deet në këcïpic ku U07.2 de thou tënë panakïm wälë e KOBIT-19 cï yök në kɛ̈ɛ̈rë görë tuany cök kë wuɔɔk SARS-CoV-2 kënë deet tënë këcïp. Thööŋde thou-kekë cin ë wuɔɔk e adɛn ë thou nyuɔthkɔ̈u kë tɛ̈kë adɛn cïnë tuany yök thïn në kaam tɔ̈ ic.
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
Në tëude gɔ̈të Jaama de Johnsn Hopkins, athëmë kɔ̈u de thou-kekë cinë wuɔɔk e 6.9% (153,822/2,240,191) mënë ye Akɔ̈nydït nïn 17, 2020.
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
Adɛt awääc në wäläya ic. Kɔ̈kë mahëm aanɔŋic athëmë kɔ̈u ë këdɛ̈ de cinë thou (KCT), kë ye adɛn ë kɔc cë thou në tuany nyuɔɔth në buɔɔtic ku jɔla athëmë kɔ̈u ë këdɛ̈ de cinë wuɔɔk. (KCW), kë ye adɛn ë kɔc cë wuɔɔk nyuɔɔth në buɔɔtic (tuany cï yök ku kë kënë yök) wɛ̈n cï tuany nɔ̈k.
These statistics are not time bound and follow a specific population from infection through case resolution.
Kekë akuën cï ke gät piny kä aace tɔ̈ thä kuka cën dun töŋ yëkï kuany cök tënë thä de wuɔɔk agut cë thä de thölde këdɛ̈.
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
Kë ce raat cï wuɔɔk ëbɛ̈n yenë guöp de lui käkë ye gëlic alëu bë thön gam në baŋde adɛn ë kɔc cë wuɔɔk.
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
Në dhamɛn ɣɔn cï tuany jä laräp pande Italy, Castiglione d'Adda, e pan thïn e nɔŋ 4600, 80 (1.7%) cë thou.
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
Lɔŋde Gangelt, tuany e lerë bec në diɛ̈rë miɛtë piöu, ku e larär bec tënë kɔc thii kor, go jɔk në kë loi yen thou bë tɔ̈ piny, ku e ce thonde KOBIT-19 ëbɛ̈n yen lëu bï week thok cë mën ekëne.
Furthermore, the German health system has not been overwhelmed.
Tënë kɔ̈k juëc, luɔide käkë pial pande German akën ë gɔ̈ɔ̈i.
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
Lɔŋde Netherlands, të cït tënë 3% alëu bïkë naŋ käkë guöp gëlic, cë mɛ̈n cïnë ye caath në riimë kɔc cë miɔ̈ɔ̈cic
69 (0.004% of the population) have been confirmed to have died from COVID-19.
69 (0.004% de adɛn ë juöric) acï deet lɔnë thou en KOBIT-19.
The impact of the pandemic and its mortality rate are different for men and women.
Luɔide tuany ku jɔla adɛnden në thuɔuic aawääc tënɔŋ rör ku diär.
Mortality is higher in men in studies conducted in China and Italy.
Thou atɔ̈ nyin nhial tënɔŋ rör në akuënë nyïc ë loi pande Caina Italy.
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
Të rilic de rɛ̈ɛ̈c tɔ̈ nhial apɛi tënë rör e 50s, kekë kaam de rör ku diär tɔ̈ cɛlic ë thiökic në 90 ëpɛth.
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
Pande Caina, cin ë thou eye 2.8 në buɔɔtic tënë rör ku 1.7 në buɔɔtic tënë diär
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
Kë ye cök ë wɛ̈t e wuöc tɔ̈ tënë rör ke diär akënë guɔ nyic lakin caga ku të ye kɔc rëër thïn akek aa lëu bïk cök ë wɛ̈t.
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
Wuɔ̈c de käkë guöp gëlic tënë rör ku diär, mäthë tap kor nyin tënë diär ku jɔla jɔ̈kde de rɛ̈kë röt de ɣäla në dhamɛn thöŋ cït yïk däkät tënë kɔc lik run ke wär run ke diär alëu bë thon dït tënë rör juak.
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
Lɔŋde Europe, 57% de kɔc cë wuɔɔk aaye rör ku jɔla 72% de kɔc cë thou në KOBIT-19 aake rör.
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Mënë Akɔ̈nydït 2020, akuma de Amërika e cë kueny wuɔɔk de KOBIT-19 cök në baŋde thönthii thïäk kekë baŋde diär ku rör.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
Aye yɔ̈ɔ̈p nyuɔth lɔn ye tuany de bairäth cït yïk Ebola, HIV, Macöu ku SARS aaye rör ku diär luɔi në dhöl wääc.
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
Adɛn dït në buɔɔtic tënë akïm, go dïk a akïm ë nyïïn tït në ayanïïn tɔ̈ në agɛn nhïm, aaye ye diär ku ka nɔŋ purtha dït lëu bï kek wuɔɔk në bairäth.
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
Akutnhom ë Pinynhom Mɛ̈t në käke Pial e cɛɛl ke Nyith e nïn 11, 2020 lɔn bïnë rin e tuanyë ya "KOBIT-19".
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
Bënyde APMP Tedros Adha om Ghebreyesus e cë ya waaric KO käc kë ye korona, BI käc kë ye bairäth, T kë käc kë ye tuany, ku jɔla 19 kë ye dhamɛnden tueŋ ë nyic ë dhoŋ bec de: 31 de Ɣɔ̈r 2019.
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Rin aake cï ke lɔc ago colë luelë rin ɣän töök puöl (cït yïk Caina), nuɔuë läi, akut ë kɔc, në löŋde pinynhom ëye luel bï ya gël bï cɛ̈k ë kɔc tier cuökë loi. Bairäth e KOBIT-19 jɔɔk acï cäk kë ye cɔl severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
APMP acë "KOBIT-19 bairäth" mat thïn ku jɔla"bairäth e mäkthul në KOBIT-19" ɣän ke jam në juööric.
Both the disease and virus are commonly referred to as "coronavirus".
Yen tuany ku bairäth aye ke cɔl "koronabairäth" karou.
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
Në dhamɛn ë dhöl bec tueŋ lɔŋde Wuhan, Caina, yen bairäth ku tuany aake ye cɔl "koronabairäth" ku "Wuhan koronabairäth".
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
Në Kön ic 2020, APMP e cë 2019-nCov ku 2019-nCoV tuany ë wëëï rilic thany cök ëke rin ke dhamɛn cekic tënë bairäth ku tuany në të cït tënë löŋ de 2015 buɔɔth ke yic cenë rinë gam ɣän ke tuany ku bairäth.
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
Rin cï ke gam KOBIT-19 ku SARS-CoV-2 ake loi kë Nyith e nïn 11, 2020.
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
Në wɛ̈të dakë yic de loi në gɛmde de käŋ, kɔc kɔ̈k ë käŋ guär bec aye käke pial ë panakïm guär bec cït yïk dulgän en um uukic ku jɔla bakde käk alir gam.
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
Në töŋ ë ye nyuɔth ic, ɣɔn le panakïm de Italy gör në thukthuk ë kën alir gam bec, ku e cë lëu rɔt tënë raan ë käŋ gam bë ke gam në ye thää den ë wïcë ye go kë thin bai këdɛ̈ wel-në liɛ̈p ku guɛ̈r thukthuk 100 wïc ke bec walk.
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Bat cï KOBIT-19 dhoŋ bec tueŋ, kuul ë lärëyic, cuök pïŋde thön apiɛth ku jɔla dhäl de thönic aacë bɛ̈n nhial në tënë bɛ̈i tuany bei thïn, medhänia, gël, yïlac ku jɔla kɔ̈k ke tuany ku yɛ̈th de bec apɛi ɣɔnlany.
Humans appear to be capable of spreading the virus to some other animals.
Kɔc akek aa lëu bïk bairäth thuäi bec tënë läi kɔ̈k.
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
Akuën ë nyïc acï wuöc ëcë yök yïc në baŋde bërë yic de bairäth tënɔŋ kadhuruk, Tut, ku jɔla ajïïth.
No medications or vaccine is approved to treat the disease.
Acën wɛl wälë wɛl gël ë guöp cï gam bïnë ke tuany alacu
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
Yɔ̈ɔ̈p de piny nhom ëbën baŋde wɛlë gël ë guöp ku wɛl de KOBIT-19 atɔ̈ dhöl ic tënë ajuɛɛr de akuma, akutnhom de thukuul ku jɔla duyɔ̈ɔ̈p ke cirga.
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
Në Köl ic, Akutnhom ë Pinynhom mɛ̈t në Pial e jɔk "ATHËMË KƆ̈C ATÖK" ku bë mëckëla de yïlany de tuany buɔth cök tënë mɛ̈t ë yic de käk ë guöp gëlic kekë lɔtueŋ piɛth.
There is no available vaccine, but various agencies are actively developing vaccine candidates.
Acën wɛl tɔ̈, lakin dutuuc juëc atɔ̈ ëke lui apɛi në luɔi de wɛl ë gël ë guöp.
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
Lon thɛɛr tënë SARS-CoV aloi emɛn në wɛ̈t ë SARS-CoV ku SARS-CoV-2 keek kerou aye ACE2 lööm bi kek alɔ në guöp ë raan ic
There are three vaccination strategies being investigated.
Anɔŋ wɛl ke gël ë guöp kädïäk kuɛny cök emɛn.
First, researchers aim to build a whole virus vaccine.
Tueŋ, duyɔ̈ɔ̈p aye ki them bïk wäl ë bairäth gël loi.
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
Lon e bairäth kënë, pïr wälë cë thou, acï täu bë käke guöp gëlic tënë guöp de raan tënë wuɔɔk de KOBIT-19 jöt.
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
Ajuɛɛr de rou, baakic de wɛl ë guöp gël ic, e thëm bë wäl ë guöp gël ic loi wɛ̈n ye käk e guöp lui jɔtnyïn tënë baakic ke bairäth.
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
Në këde SARS-CoV-2, kekë yɔ̈ɔ̈p cït ë käkä aye ke nhïm täu në protin ke S-spike wɛ̈n ye bairäth kuɛny bë luëŋ në noŋ ë dɔm de ACE2 ic
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
Ajuɛɛr de diäk e këde wɛl ë gël ë de nucleic acid (DNA wälë wɛlke RNA e dhöl jöt de gɔ̈lë wäl de tuöm).
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
Wɛl cï ke käŋ them tënɔŋ töŋ ajuɛɛr kä alëu bi them në piathde ku lajiŋ. Kë Köl e nïn 16, 2020, thëm tueŋ ë panakïm de wäl e jöök në kɔc cë röt gäm ke ŋuan pande Seatle
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
Wɛl ake nɔŋic cäät cï thian cën këraac tɔ̈ ye yic ë lööm tënë bairäth ë jɔk tuany. Käk ë guöp gël ic e nuɛtë rɔt cök piny aci mɛɛkic kë ye yen ë luɔi de wäl jit cök tënë SARS-COV-2, lakin anɔŋ ariɛr apɛi.
There are more than 300 active clinical trials underway as of April 2020.
Anɔŋ athëm lui tɔ̈ dhölic wär 300 mënë Akɔ̈nydït 2020.
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
Athëm kadhorou aake bɔ nhial cï ke gam wɛ̈nthɛɛr ë ke yennë malaria alacu kë nɔŋic yïk akuën ë nyïc tënë kolorkuin ë nyin pïu wälë kolorkuin de ubup.
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Wɛl ke gël ë guöp tënë bairäth cï ke dhuɔ̈k në kanadɛn ë luɔi aakek aa loi yɔ̈ɔ̈p de Cainïth, kekë atëk ë thëmthëm de III tënë remdesivir në bɛ̈i juëc ic ëbën ë tɔ̈ ë bï caal në thök Akɔ̈nydït.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Dhöl ë röt cɛɛthëic në akïm në baŋde lɔtueŋ ë luɔi de wäl de KOBIT-19 ku wɛl tɔ̈ në thäpic e tɔ̈, mënë Akɔ̈nydït 2020. Wɛl juëc de gël ë bairäth tɔ̈ aaye ke them në baŋde yïlany de KOBIT-19, ë nɔŋic remdesivir, kolorkuin de ubup ku jɔla kolorkuin ë nyin pïu, lopinavir/ritonavir ku lopinavir/ritonavir cï mät kekë interferon beta.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Anɔŋ kë ŋɔ̈thë lëu bï bɛ̈n nhial piɛth nyuɔth në remdesivir, mënë Kol 2020.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
Cot ë röt tueŋ në baŋde panakïm e cï tïŋ tënë ayanïn e dekë remdesivir.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Atëk ë thëmthëm de III ë panakïm aaloi ke lɔŋde Amërika, Caina ku Italy. Kolorkuin e ye loi thɛɛr bïnë malaria ya alacu, e kuen Caina në Nyith ic 2020, kekë nëtïja akërnhiaam.
However, there are calls for peer review of the research.
Yennë kɛy, anɔŋ cöt wïcë ye kubï yɔ̈ɔ̈p bɛ nyɔkë cɛɛthëic në kä riëc.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Bäny ke Korea ku Caina acïk thany cök bë ya kolorkuin en e loi.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Kë yen, thukulde Wuhan de bairäth, në kë yen wäl ë dëk gam kë ye töŋ kor na köl tökic, ka ye tïŋ lɔn dëk na rou në köl tökic kë rac apɛi ku alëu bë ya thou.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
Kë Kol e nïn 28, 2020, go FDA dëk de kolorkuin ë nyin pïu ku kolorkuin de ubup täu kë teemë thïn në löŋ kë kën dïktoor loi yïlac tënë kɔc tuany në KOBIT-19 gam. Warɛŋ de bɔ̈ɔ̈thë lööŋic de Cainïthdɛn de 7th e interferon mat thïn, ribavirin wälë umifenovir bï ya dëk kë kënë KOBIT-19.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Thönthii kä kërnhiaam e ye nyuɔth lɔn ye dëk dït dë ribavirin aaplɛth bïk SARS-CoV-2 ya nyuɔth në vitro ic.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Nitazoxanide acï thany cök në akuën lɔtueŋ në baŋde vivo bat cïnë ye nyuɔth kë cäth dë ye kɔ̈c ke cë latueŋ në SARS-CoV-2 ic. Acï akuënkuën nyuɔth lɔn ye lɔpiny tueŋde protin ë riök transmembrane protease serine 2 (TMPRSS2) e lajik në luëŋthïn dë SARS-CoV-2 në baŋde liääpde kekë ACE2 ë dɔm.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Akuën ë kolorkuin dë ubup ku kolorkuin ë nyin pïu kë nɔŋ wälë cën aztjromycin anɔŋ kä juëc dakic apɛi wɛ̈n e wuöt ke wɛl gël ëke cë lööm käk ke wɛ̈rë guöp ë pial apiɛth ë cë ber lɔtueŋ kek akuën. Oseltamivir ace SARS-CoV-2 ë muökthïn në vitro ic ku acën nhom luɔi në yïlany de KOBIT-19 ic.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Atiɛktiɛk de cytokine alëu bë käŋ bɛ ladɔknyïn pe tënë kana de KOBIT-19 rilic.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Anɔŋ kën ë ye nyuɔth lɔn ye kolorkuin ë nyin pïu lëu ben naŋ kë ye gël në-käk atiɛktiɛk. Tocilizumab acï mat në kä buɔthë ke yïlac cök në akutnhom ë käk ë pial pa dë Caina bat cïnë akuën thiin kor thöl.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Atɔ̈ kë lɔtueŋ në atëkë 2 dë athëm cï wɛɛr ëpɛth në baŋde pande Italy bat cen nëtïja piɛth nyuɔth tënë kɔc nɔŋ tuany rilic.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Ëcï liääp kekë juätë ferritin riɛm them agorë atiɛktiɛk de cytokine yök, eeye tɔ̈ bï ya rɛk nhom kekë lɔtueŋ käkä, ëke këk e takic kë ke këk jɔk thou tënë kɔc cë wuɔɔk.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Kë wääc kekë interleukin-6 ë dɔm ecï gam në FDA ë cï täu në akuën thɛɛr cïëën de yïlanyde steroid rilnhom dë cytokine cïnë cït luɔny bec ë wel kök wääc nhom, cökë piny ë pial dë CAR T cell, në 2017 ic.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Agut cë mɛn, acën kë cï wɛɛr, cï muök nhompiny ë ye nyuɔth lɔn e tocilizumab yen lui apiɛth kekë yïlany de CRS.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Gɛmde käkë guöp gëlic cï ke laathic kua ladöt tënɔŋ kɔc cë tuany ku jɔl kï pial tënɔŋ KOBIT-19 tënë kɔc wïc ke atɔ̈ në ajuɛrde görë cökic kë cë dhöl de wäl ë tuöm.
This strategy was tried for SARS with inconclusive results.
Yennë ajuɛr kënë acï them tënë SARS kekë nëtïjaa kënë thölthok.
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
Luɔide bairäth bë dhuk piny en e dhöl ŋɔth kɔc në kë puöth ë bï loi bïnë käke juërë pial de käkë guöp gëlic lëu bë SARS-CoV-2 ya gël.
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
Dhöl kök, cït yïk käk ë kɔ̈c në käke guöp gëlic de räl ke cytotoxicity ku/wälë phagocytosis, alëu bë rɔt lëu.
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
Nuɔu kök ke käk ë pial geric de gëlë guöp, cë mënë, luɔide käke gëlë guöp cï ke guör ë cäätdɛnic, atɔ̈ në luɔi de lɔtueŋic.
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
Luɔide juätë riɛmë thökde tuany, kë nɔŋic dhuɔth lau ë riɛm tënɔŋ ayanïïn cë gup pial ku nɔŋic käke gëlë guöp cï ruök ë bairäth kän, alëu bï dhilë juak nyin agorë dac gambec.
Coronavirus diseases, a group of closely related syndromes
Tuɛnytuɛny ke koronabairäth, akutnhom dë cït ruäï thiökic
Li Wenliang, a doctor at Central Hospital of Wuhan, who later contracted and died of COVID-19 after raising awareness of the spread of the virus.
Li Wenliang, e dïktor de Panakïm dït Cɛl de Wuhan, wɔn lɔwuɔk ku thou në KOBIT-19 batë luel en larär bec dë bairäth.